drugset / Trial / NCT02827903

Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia

NCT02827903

Phase 3 Completed 237 enrolled Jeil Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

Compare the Efficacy and Safety of Metformin/Rosuvastatin Combination Therapy With Metformin or Rosuvastatin Monotherapy in Patients With Type 2 Diabetes and Dyslipidemia

Timeline

Start
2016-01-15
Primary completion
2017-11-21
Completion
2018-03-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule
Subject Rosuvastatin Small molecule